We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lonza to Invest in Portsmouth, NH (USA) Site, Including Mid-Scale Biologics
News

Lonza to Invest in Portsmouth, NH (USA) Site, Including Mid-Scale Biologics

Lonza to Invest in Portsmouth, NH (USA) Site, Including Mid-Scale Biologics
News

Lonza to Invest in Portsmouth, NH (USA) Site, Including Mid-Scale Biologics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lonza to Invest in Portsmouth, NH (USA) Site, Including Mid-Scale Biologics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lonza Pharma & Biotech
announced the
investment
in
a new phase of development at their Portsmouth
, NH
(USA)
site.
The
expansion will include mid-scale
mammalian
capacity
and
the addition of new cell-therapy
suites.
With this
latest
round of growth, Lonza
Portsmouth
confirms its position
as a
leading
-
house
in
biologics
manufacturing
and
ensures
capacity for customers in the
years ahead.

Lonza is installing multiple 6,000L bioreactors at the site to
meet
existing and new
customers' needs
,
with building
expected to
start in
late
2018.
Further expansion of mid-scale capacity
is seen as a key
area
of growth
by
the Swiss-based manufacturer
, driven by several factors including a
favorable regulatory environment for developing products
for
niche indications
. Lonza’s Portsmouth site
is ideally
placed
for the
addition of mid
-
scale capacity within
their
existing global network, which ranges from
small
,
single
-
use
bioreactors
to
large
-
scale
assets.

The new facilities have been designed to ensure
reliable
delivery of innovative medicines.
With
a
strong
focus on
automation
,
Lonza
is implementing
full-suite process
analytic technology (
PAT) and advanced multi-variate
analysis (MVA) to ensure consistent performance.
The
hybrid facility
,
which also incorporates state-of-the-art
,
single-use technologies for simplified processing,
will be
installed in
an
existing building.


These new facilities have been designed specifically
to
deliver for
our
customers
and their patient
s
,” commented
Marc Funk, COO
Lonza Pharma & Biotech
. “They will be
enabled by cutting-edge technology
developed with
our
R&D team and the decades of expertise at our Portsmouth
site”

In addition, Lonza is
installing
multiple cell-therapy suites at
the Portsmouth site. In
February
2018, the company
established centers of excellence in cell and gene
therapy
across its network
,
placing
Portsmouth
as
a
clinical and
commercial manufacturing center in this emerging
technology.
Customers will have access to facilities for
phase I through to commercial
manufacturing
under one
roof,
expected to be fully operational
by late 2018
.
Advertisement